Get the Stockscreener App
2.00
4.76%
-0.10
Allogene Therapeutics Inc stock is traded at $2.00, with a volume of 7.76M.
It is down -4.76% in the last 24 hours and up +12.36% over the past month.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
See More
Previous Close:
$2.10
Open:
$2.1
24h Volume:
7.76M
Relative Volume:
0.68
Market Cap:
$690.31M
Revenue:
$22,000
Net Income/Loss:
$-173.76M
P/E Ratio:
-2.6038
EPS:
-0.7681
Net Cash Flow:
$-109.53M
1W Performance:
-3.85%
1M Performance:
+12.36%
6M Performance:
+16.96%
1Y Performance:
+58.73%
1-Day Range:
$1.94
$2.10
1-Week Range:
$1.94
$2.185
52-Week Range:
$0.9842
$4.46
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.00 | 690.31M | 22,000 | -173.76M | -109.53M | -0.7681 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-10-26 | Resumed | Jefferies | Buy |
| Jan-09-26 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| May-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Allogene Therapeutics (ALLO) price target increased by 16.66% to 8.83 - MSN
Cancer cell therapy pioneer Allogene’s new CEO is talking about a new revolution - The Business Journals
Form 4 Allogene Therapeutics Inc For: 6 July By Investing.com - Investing.com Canada
Allogene Therapeutics (ALLO) CEO granted 476,190 options and 134,530 RSUs - Stock Titan
ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ - Stocktwits
Allogene Therapeutics shows promise with ALPHA3 trial and ALLO-329, cutting losses and extending cash runway. - Pluang
Allogene Therapeutics: High-Upside Bet On The Next Wave Of CAR-T Innovation (NASDAQ:ALLO) - Seeking Alpha
ALLO News | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Allogene at H.C. Wainwright conference: cema-cel data lift strategy By Investing.com - Investing.com Nigeria
Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView
Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions - Yahoo Finance
Price to earnings forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView
Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Enterprise value to revenue forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Price to book forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView
Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Allogene Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLO) - TradingView
Why is Allogene Therapeutics (ALLO) down 12.2% since last earnings report? - MSN
ALLO Forecast — Price Target — Prediction for 2027 - TradingView
Allogene Therapeutics unveils strategy to overcome autologous CAR T cell therapy limitations - Traders Union
Allogene Therapeutics (ALLO) Edges Higher Near Key Resistance LevelInsider Selling Alerts - dars.gov.et
Recent pharma exec shake-ups signal strategic shifts - Pharma Voice
Form 4 Allogene Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria
Allogene (ALLO) director Kazam converts 47,700 RSUs and receives 95,400-unit equity grant - Stock Titan
Allogene Therapeutics (NASDAQ: ALLO) grants director 95,400 RSUs - Stock Titan
Allogene Therapeutics (ALLO) director receives 144,400 stock options grant - Stock Titan
Allogene Therapeutics (ALLO) director receives 95,400 RSU equity award - Stock Titan
Allogene (ALLO) director Owen Witte awarded 95,400 RSUs with deferred delivery - Stock Titan
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan
Allogene (ALLO) director awarded 95,400 RSUs with deferred share delivery - Stock Titan
Form 424B5 Allogene Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Allogene Therapeutics (NASDAQ: ALLO) doubles authorized shares and files $135M ATM plan - Stock Titan
Allogene (NASDAQ: ALLO) launches $135M ATM program with TD Cowen at $2.00 ref - Stock Titan
Allogene Therapeutics Activates First Clinical Sites for Pivotal Phase 2 Trial of Cema-Cel - CRISPR Medicine News
ALLO: All proposals, including director elections and share increase, were approved without contest - TradingView
ALLO: All proposals passed, including director elections and share authorization increase - TradingView
Allogene Therapeutics Inc (ALLO) Institutional Confidence - TradingKey
Allogene Therapeutics Inc (ALLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allogene Therapeutics Inc (ALLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allogene Therapeutics Inc (ALLO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease - Insider Monkey
Allogene Therapeutics Inc (ALLO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Allogene Therapeutics Inc (ALLO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Allogene Therapeutics Inc (ALLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Allogene Therapeutics Stock Surges on Optimistic Trial Results and Price Target Increase - timothysykes.com
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):